Trial ID or NCT#

NCT01822496

Status

RECRUITING

Purpose

This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.

Official Title

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Billy W. Loo, Jr., MD, PhD, DABR
Radiation oncologist, Thoracic specialist
Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
Joel Neal, MD, PhD
Medical oncologist, Thoracic specialist
Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center
Maximilian Diehn, MD, PhD
Radiation oncologist
Assistant Professor of Radiation Oncology (Radiation Therapy)
Kavitha Ramchandran
Medical oncologist, Palliative medicine doctor, Thoracic specialist, Internal medicine doctor
Clinical Assistant Professor, Medicine - Oncology
Millie Das, MD
Medical oncologist, Thoracic specialist
Clinical Assistant Professor, Medicine - Oncology
Heather Wakelee, MD
Medical oncologist, Thoracic specialist
Professor of Medicine (Oncology) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061